Single peptide Vial strength 1 mg
IGF-1 LR31 mg
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
IGF-1 LR3, explained simply
A synthetic IGF-1 analogue designed to bind less strongly to certain IGF-binding proteins.
Research area
Tissue growth, metabolism and IGF-1 receptor signalling
How it works
Structural changes alter its binding to carrier proteins and systemic exposure relative to native IGF-1.
Why it matters
The profile shows why findings for natural IGF-1 or related medicines are not automatically evidence for LR3.
What has been observed
Research on the IGF-1 family discusses anabolic and metabolic effects but combines analogue research with clinical data on different compounds.
Effects and points to consider
Extrapolating between molecules needs care; interference with blood-glucose regulation is clinically relevant.
01 / Vial strength 1 mg
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Vial contents | 1 mg IGF-1 LR3 |
|---|---|
| Final volume | 3 mL |
| Concentration | 0.33 mg/mL |
| One U-100 unit | 3.33 mcg in 0.01 mL |
Standard / Gradual Approach (3 mL = ~0.333 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 20 mcg (0.02 mg) | 6 units (0.06 mL) |
| Weeks 3–4 | 40 mcg (0.04 mg) | 12 units (0.12 mL) |
| Weeks 5–8 | 50 mcg (0.05 mg) | 15 units (0.15 mL) |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.